Overview: Tacrolimus CYP3A5 Genotyping TestIntroduction: The Tacrolimus CYP3A5 Genotyping Test detects CYP3A5 mutations to guide transplant therapy, preventing rejection. Following 2023 AST guidelines, it uses PCR for high specificity, supporting genetic screening. This test is critical for guiding treatment planning and improving outcomes in pharmacogenomics for transplant patients.
Other Names: Tacrolimus Genotyping Assay, CYP3A5 Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting pharmacogenomics standards for diagnostic accuracy.
Historical Milestone: CYP3A5 genotyping began in the 2000s with pharmacogenomics research. PCR methods improved in the 2010s, enhancing precision.
Purpose: Detects CYP3A5 mutations to guide tacrolimus dosing, preventing transplant rejection.
Test Parameters: 1. CYP3A5 Genotype
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of transplant or immunosuppressive therapy.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document transplant history, rejection episodes, or immunosuppressive therapy. Include current medications, especially tacrolimus.
Consent: Written consent required, detailing the tests purpose, transplant therapy implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect CYP3A5 mutations. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for transplant therapy optimization.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Sample quality impacts specificity.
Clinical Significance: CYP3A5 mutations guide tacrolimus dosing, optimizing immunosuppression and preventing rejection. Non-mutated genotypes may require standard dosing.
Specialist Consultation: Consult a transplant specialist or pharmacologist for result interpretation and dosing adjustments.
Additional Supporting Tests: Tacrolimus levels, kidney function tests, or rejection biomarkers to monitor transplant health.
Test Limitations: Specific to CYP3A5; other genetic factors may influence tacrolimus metabolism. Clinical correlation is needed.
References: AST Transplant Guidelines, 2023; Transplantation, Haufroid V, 2022.
